151 related articles for article (PubMed ID: 19013180)
1. CDC25A functions as a novel Ar corepressor in prostate cancer cells.
Chiu YT; Han HY; Leung SC; Yuen HF; Chau CW; Guo Z; Qiu Y; Chan KW; Wang X; Wong YC; Ling MT
J Mol Biol; 2009 Jan; 385(2):446-56. PubMed ID: 19013180
[TBL] [Abstract][Full Text] [Related]
2. Specificity of cyclin D1 for androgen receptor regulation.
Petre-Draviam CE; Cook SL; Burd CJ; Marshall TW; Wetherill YB; Knudsen KE
Cancer Res; 2003 Aug; 63(16):4903-13. PubMed ID: 12941814
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mashima T; Okabe S; Seimiya H
Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
[TBL] [Abstract][Full Text] [Related]
5. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
Cheng H; Snoek R; Ghaidi F; Cox ME; Rennie PS
Cancer Res; 2006 Nov; 66(21):10613-20. PubMed ID: 17079486
[TBL] [Abstract][Full Text] [Related]
6. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
7. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
8. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
9. TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3.
Mu X; Chang C
Prostate; 2003 Oct; 57(2):129-33. PubMed ID: 12949936
[TBL] [Abstract][Full Text] [Related]
10. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
Heemers HV; Regan KM; Dehm SM; Tindall DJ
Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004
[TBL] [Abstract][Full Text] [Related]
11. Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer.
Cano P; Godoy A; Escamilla R; Dhir R; Onate SA
Cancer Res; 2007 Jan; 67(2):511-9. PubMed ID: 17234758
[TBL] [Abstract][Full Text] [Related]
12. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
13. Sterol regulatory element-binding protein-1c represses the transactivation of androgen receptor and androgen-dependent growth of prostatic cells.
Suh JH; Gong EY; Kim JB; Lee IK; Choi HS; Lee K
Mol Cancer Res; 2008 Feb; 6(2):314-24. PubMed ID: 18245227
[TBL] [Abstract][Full Text] [Related]
14. Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells.
Ma AH; Xia L; Desai SJ; Boucher DL; Guan Y; Shih HM; Shi XB; deVere White RW; Chen HW; Tepper CG; Kung HJ
Cancer Res; 2006 Sep; 66(17):8439-47. PubMed ID: 16951154
[TBL] [Abstract][Full Text] [Related]
15. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.
Kinoshita M; Nakagawa T; Shimizu A; Katsuoka Y
Int J Urol; 2005 Apr; 12(4):390-7. PubMed ID: 15948728
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells.
Azuma K; Nakashiro K; Sasaki T; Goda H; Onodera J; Tanji N; Yokoyama M; Hamakawa H
Biochem Biophys Res Commun; 2010 Jan; 391(1):1075-9. PubMed ID: 20004643
[TBL] [Abstract][Full Text] [Related]
17. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor and invasion in prostate cancer.
Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
[TBL] [Abstract][Full Text] [Related]
19. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.
Sterbis JR; Gao C; Furusato B; Chen Y; Shaheduzzaman S; Ravindranath L; Osborn DJ; Rosner IL; Dobi A; McLeod DG; Sesterhenn IA; Srivastava S; Cullen J; Petrovics G
Clin Cancer Res; 2008 Feb; 14(3):758-63. PubMed ID: 18245536
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte nuclear factor-3 alpha (HNF-3alpha) negatively regulates androgen receptor transactivation in prostate cancer cells.
Lee HJ; Hwang M; Chattopadhyay S; Choi HS; Lee K
Biochem Biophys Res Commun; 2008 Mar; 367(2):481-6. PubMed ID: 18178153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
